The i-Technology Media!
Register | Log in
   
 
.NET  ·  AJAX  ·  CLOUD  ·  ECLIPSE  ·  FLEX  ·  OPEN WEB  ·  iPHONE  ·  JAVA  ·  LINUX  ·  OPEN SOURCE  ·  ORACLE  ·  PBDJ  ·  SEARCH  ·  SILVERLIGHT  ·  SOA  ·  VIRTUALIZATION  ·  WEB 2.0  ·  WIRELESS  ·  XML
YOUR FEEDBACK
Data Services Made Easy for Adobe Flex Applications
erdem wrote: çet ...
Dec. 4, 2008 05:34 AM
Cloud Computing Conference
March 30 - April 1, New York
Register Today and SAVE !..
Did you read today's front page stories & breaking news?
Live Google News by SYS-CON!

TOP THREE LINKS YOU MUST CLICK ON


From the Wires
Launches of Humira, Golimumab and Orencia for Treatment of Ulcerative Colitis Will Drive Annual Five Percent Market Growth
Expected Approvals of Biologic Agents Will Expand Treatment Options for Patients Who Fail Conventional Drug Treatment, According to a New Report from Decision Resources

By: PR Newswire
Aug. 13, 2008 08:00 AM

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual five percent growth through 2017 in the ulcerative colitis drug market will be driven by strong uptake of Abbott/Eisai's Humira, Centocor/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's golimumab and Bristol-Myers Squibb's Orencia, following the expected approvals and launches of these three biologic agents for ulcerative colitis by 2017.

The new Pharmacor report entitled Ulcerative Colitis finds that Humira and golimumab -- as maintenance therapies -- will drive nearly two-thirds of the growth in the ulcerative colitis market in the United States, France, Germany, Italy, Spain and the United Kingdom over the next ten years. Humira and golimumab will expand treatment options for moderate to severe patients who fail treatment with conventional pharmacotherapies, posing a threat to Centocor/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade. Additionally, the approval of Orencia by 2012 for the treatment of moderate to severe disease as an acute and maintenance therapy, will expand treatment options for patients who fail treatment with tumor necrosis factor-alpha (TNF-alpha) inhibitors.

"We project golimumab may have an advantage over its predecessors within the TNF-alpha inhibitor class-specifically Remicade and Humira-because the drug is being investigated for both intravenous and subcutaneous delivery," said Kathryn Benton, analyst at Decision Resources. "However, we expect Humira to outperform golimumab in ulcerative colitis sales due to Humira's earlier market entry and more well-established long-term safety profile."

The report also finds that the uptake of Shire/Takeda/Giuliani's Lialda/Mezavant/Mezavant XL and its launch in additional countries will contribute to market growth, owing to the agent's improved dosing convenience and its premium price compared to currently marketed drugs in its class. Lialda/Mezavant/Mezavant XL, the most recently approved oral 5- aminosalicylate, has launched in the United States, Germany and the United Kingdom and is expected to launch in the remaining European markets in late 2008.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Elizabeth Marshall
    Decision Resources, Inc.
    781-296-2563
    emarshall@dresources.com

SOURCE Decision Resources, Inc.

Published Aug. 13, 2008
Copyright © 2008 SYS-CON Media. All Rights Reserved.
About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SUBSCRIBE TO THE WORLD'S MOST POWERFUL NEWSLETTERS
SUBSCRIBE TO OUR RSS FEEDS & GET YOUR SYS-CON NEWS LIVE!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON FEATURED WHITEPAPERS

ADS BY GOOGLE

ADVERTISE   |   MAGAZINE SUBSCRIPTIONS   |   FREE BREAKING-NEWSLETTERS!   |   SYS-CON.TV   |   BLOG-N-PLAY!   |   WEBCAST   |   EDUCATION   |   RESEARCH

.NET Developer's Journal - .NETDJ   |   ColdFusion Developer's Journal - CFDJ   |   Eclipse Developer's Journal - EDJ   |   Enterprise Open Source Magazine - EOS
Open Web Developer's Journal - OPENWEB   |   iPhone Developer's Journal - iPHONE   |   Virtualization - Virtualization   |   Java Developer's Journal - JDJ   |   Linux.SYS-CON.com
PowerBuilder Developer's Journal - PBDJ   |   SEO / SEM Journal - SJ   |   SOAWorld Magazine - SOAWM   |   IT Solutions Guide - ITSG   |   Symbian Developer's Journal - SDJ
WebLogic Developer's Journal - WLDJ   |   WebSphere Journal - WJ   |   Wireless Business & Technology - WBT   |   XML-Journal - XMLJ   |   Internet Video - iTV
Flex Developer's Journal - Flex   |   AJAXWorld Magazine - AWM   |   Silverlight Developer's Journal - SLDJ   |   PHP.SYS-CON.com   |   Web 2.0 Journal - WEB2
Apache   |   CMS   |   CRM   |   HP   |   Oracle Journal   |   Perl   |   Python   |   Red Hat   |   Ruby on Rails   |   SAP   |   SaaS

SYS-CON MEDIA:   ABOUT US   |   CONTACT US   |   COMPANY NEWS   |   CAREERS   |   SITE MAP
SYS-CON EVENTS:   |  AJAXWorld Conference & Expo  |  iPhone Developer Summit  |  OpenWeb Developer Summit  |  SOA World Conference & Expo  |  Virtualization Conference & Expo
INTERNATIONAL SITES:   India  |  U.K.  |  Canada  |  Germany  |  France  |  Australia  |  Italy  |  Spain  |  Netherlands  |  Brazil  |  Belgium
 Terms of Use & Our Privacy Statement     About Newsfeeds / Video Feeds
Copyright ©1994-2008 SYS-CON Publications, Inc. All Rights Reserved. All marks are trademarks of SYS-CON Media.
Reproduction in whole or in part in any form or medium without express written permission of SYS-CON Publications, Inc. is prohibited.
 
close this window